Home > Cardiology > AHA 2019 > Trials in Electrophysiology and Left Ventricular Function > Early apixaban safe as secondary prevention of stroke from AF

Early apixaban safe as secondary prevention of stroke from AF

Presented By
Dr Arthur Labovitz, University of South Florida, USA
Conference
AHA 2019
Trial
AREST

Dr Arthur Labovitz (University of South Florida, USA) presented the initial results of the pilot, open-label, parallel-group, multicentre, randomised controlled Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation (AREST) trial [1].

The study intended to determine the optimal timing of anticoagulation initiation after atrial fibrillation (AF)-induced acute ischaemic stroke (AIS), which is associated with larger infarct volumes. Previous landmark randomised trials have all waited weeks or months to begin anticoagulation after a stroke, but this trial aimed to establish the clinical value of early intervention. To that end, the safety and efficacy of early anticoagulation were evaluated based on stroke size, secondary prevention of ischaemic stroke, and risks of subsequent haemorrhagic transformation.

Patients were randomised 1:1 to receive early apixaban...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on